2-Phenylpropanol is a chiral organic compound with the formula C9H12O. It is a colorless liquid that is insoluble in water. 2-Phenylpropanol is used as an intermediate in the synthesis of various pharmaceuticals and other organic compounds. It is a precursor to the widely-used pharmaceutical propranolol, a beta blocker used to treat hypertension and other cardiovascular conditions. 2-Phenylpropanol is also used in the synthesis of perfumes and flavorings. It is a versatile intermediate in organic synthesis due to its reactivity and the presence of a chiral center. Researchers study 2-phenylpropanol to develop new synthetic routes to pharmaceuticals and other useful compounds.'
2-phenylpropanol-1: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 14295 |
| CHEMBL ID | 2323841 |
| CHEBI ID | 193640 |
| SCHEMBL ID | 1260 |
| MeSH ID | M0494699 |
| Synonym |
|---|
| LS-13645 |
| hydratropyl alcohol |
| hydratropic alcohol |
| 1-propanol, 2-phenyl- |
| nsc-5232 |
| .beta.-methylphenethyl alcohol |
| nsc5232 |
| 1-hydroxy-2-phenylpropane |
| phenethyl alcohol, .beta.-methyl- |
| benzeneethanol, .beta.-methyl- |
| 2-phenyl-1-propanol |
| 2-phenylpropyl alcohol |
| .beta.-phenylpropyl alcohol |
| 1123-85-9 |
| beta-methylphenethyl alcohol |
| einecs 214-379-7 |
| benzeneethanol, beta-methyl- |
| nsc 5232 |
| 2-phenylpropan-1-ol |
| alpha-methyl phenylethyl alcohol |
| 2-phenylpropanol-1 |
| phenethyl alcohol, beta-methyl- |
| ai3-28634 |
| beta-methylbenzeneethanol |
| 2-methyl-2-phenylethanol |
| fema no. 2732 |
| beta-phenylpropyl alcohol |
| brn 1906760 |
| 2-phenyl-1-propanol, >=97%, fg |
| 2-phenyl-1-propanol, 97% |
| FT-0691839 |
| P0813 |
| CHEBI:193640 |
| A802564 |
| AKOS009156532 |
| 27zyz88dwu , |
| 2-06-00-00477 (beilstein handbook reference) |
| unii-27zyz88dwu |
| tox21_302341 |
| dtxsid8037756 , |
| cas-1123-85-9 |
| NCGC00255620-01 |
| dtxcid6017756 |
| 2-phenyl-propan-1-ol |
| FT-0605320 |
| FT-0605151 |
| FT-0613308 |
| (+/-)-.beta.-methylbenzeneethanol |
| 2-phenylpropanol |
| (rs)-2-phenyl-1-propanol |
| (+/-)-2-phenylpropanol |
| (+/-)-2-phenyl-1-propanol |
| .beta.-methylphenethyl alcohol [fhfi] |
| CHEMBL2323841 |
| (rs)-2-phenyl-propan-1-ol |
| SCHEMBL1260 |
| W-109647 |
| mfcd00004736 |
| fema 2732 |
| b-hydroxycumene |
| b-methylbenzeneethanol, 9ci |
| b-methylphenethyl alcohol |
| 98103-87-8 |
| E78194 |
| Q27254245 |
| SY036226 |
| beta-methylphenethylalcohol |
| BAA12385 |
| EN300-258842 |
| CS-0130519 |
| SY004270 |
| SY036227 |
| Class | Description |
|---|---|
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.7653 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743079 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 68.5896 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.9588 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID728444 | Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 1 mM at pH 5.4 by circular dichroism analysis | 2013 | Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7 | The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||